Alzheimer's Association, Individuals Living With Alzheimer's Urge FDA to Grant Traditional Approval for Lecanemab
May 26, 2023
May 26, 2023
CHICAGO, Illinois, May 26 (TNSgov) -- The Alzheimer's Association issued the following news release on May 25, 2023:
The Alzheimer's Association and members of the Association's Early Stage Advisory Group submitted comments to the FDA Peripheral and Central Nervous System Drugs Advisory Committee, urging it to recommend traditional approval of Leqembi(TM) (lecanemab, Eisai). Leqembi was granted accelerated approval in January 2023 and the FDA will complete its review . . .
The Alzheimer's Association and members of the Association's Early Stage Advisory Group submitted comments to the FDA Peripheral and Central Nervous System Drugs Advisory Committee, urging it to recommend traditional approval of Leqembi(TM) (lecanemab, Eisai). Leqembi was granted accelerated approval in January 2023 and the FDA will complete its review . . .